Document:

Exhibit 10.3

 Exhibit 10.3 
 CONFIDENTIAL SEPARATION AGREEMENT 
 AND GENERAL RELEASE OF ALL CLAIMS 

This Confidential Separation Agreement and General Release of All Claims (“Separation Agreement”) is made by and between La Jolla
Pharmaceutical Company (“Company”) and Gail A. Sloan (“Executive”) with respect to the following facts: 
 A.
Executive is currently employed by Company as Chief Financial Officer pursuant to an Employment Agreement dated May 24, 2010 (“Employment Agreement”); 
 B. Executive’s employment with Company will be terminated without cause pursuant to paragraph 3.2 of the Employment Agreement. The termination effective date will be January 19, 2012 (“Separation
Date”). Executive will receive Executive’s final paycheck, including any unused and accrued vacation time, on the Separation Date. Company wishes to reach an amicable separation with Executive and assist Executive’s transition to
other employment; 
 C. The parties wish to supersede the severance provisions in paragraph 3.6(a), (b) and (c) of the
Employment Agreement and proceed, instead, in accordance with the terms and conditions in this Separation Agreement; and 
 D. The parties
desire to settle all claims and issues that have, or could have been raised, in relation to Executive’s employment with Company and arising out of or in any way related to the acts, transactions or occurrences between Executive and Company to
date, including, but not limited to, Executive’s employment with Company or the termination of that employment, on the terms set forth below. 
 THEREFORE, in consideration of the promises and mutual agreements hereinafter set forth, it is agreed by and between the undersigned as follows: 

1. Severance Package. Company agrees to provide Executive with the following payments and benefits (“Severance Package”) to which
Executive is not otherwise entitled absent the signing of a release. Executive acknowledges and agrees that this Severance Package constitutes adequate legal consideration for the promises and representations made by Executive in this Separation
Agreement. 
 1.1 Severance Payment. Company agrees to provide Executive with a severance payment of $62,222.00 less all
appropriate federal and state income and employment taxes (“Severance Payment”). The Severance Payment will be made in a lump sum cash payment on the Separation Date, by wire transfer to a bank account designated by Executive, provided
Executive has signed this Separation Agreement. 
 1.2 Retention of Company Property. Company agrees to allow Executive to retain
the Company-issued iPad, iPhone and laptop computer in Executive’s possession. 
 1.3 Resignation. Company agrees to
characterize Executive’s separation as a voluntary resignation in any public statement or request for reference. Notwithstanding the foregoing, the Company shall be permitted to file this Agreement with the Securities and Exchange Commission to
the extent required under the Securities Exchange Act of 1934, as amended. 
 1.4 No Contest of Unemployment. Company agrees that
it will not contest any claims Executive may file for unemployment insurance benefits and will promptly process any paperwork related to same. 

 2. Express Waiver and Return of Stock Options. By signing this Separation Agreement, Executive
expressly waives her right to all Company stock options provided pursuant to the Employment Agreement and relinquishes to the Company all vested and unvested stock options. 
 3. General Release. 
 3.1 Executive unconditionally, irrevocably and absolutely releases and
discharges Company, and any parent and subsidiary corporations, divisions and affiliated corporations, partnerships or other affiliated entities of Company, past and present, as well as their Executives, officers, directors, agents, successors and
assigns (collectively, “Released Parties”), from all claims related in any way to the transactions or occurrences between them to date, to the fullest extent permitted by law, including, but not limited to, Executive’s employment with
Company, the termination of Executive’s employment, and all other losses, liabilities, claims, charges, demands and causes of action, known or unknown, suspected or unsuspected, arising directly or indirectly out of or in any way connected with
Executive’s employment with Company. This release is intended to have the broadest possible application and includes, but is not limited to, any tort, contract, common law, constitutional or other statutory claims, including, but not limited to
alleged violations of the California Labor Code or the federal Fair Labor Standards Act, Title VII of the Civil Rights Act of 1964 and the California Fair Employment and Housing Act, the Americans with Disabilities Act, the Age Discrimination
in Employment Act of 1967, as amended (“ADEA”), and all claims for attorneys’ fees, costs and expenses. However, this general release is not intended to bar any claims that, by law, may not be waived, such as claims for workers’
compensation benefits, unemployment insurance benefits, statutory indemnity, and any challenge to the validity of Executive’s release of claims under the ADEA (“ADEA Claims”), as set forth in this Separation Agreement. 

3.2 Executive acknowledges that Executive may discover facts or law different from, or in addition to, the facts or law that Executive knows or
believes to be true with respect to the claims released in this Separation Agreement and agrees, nonetheless, that this Separation Agreement and the release contained in it shall be and remain effective in all respects notwithstanding such different
or additional facts or the discovery of them. 
 3.3 Executive declares and represents that Executive intends this Separation Agreement to
be complete and not subject to any claim of mistake, and that the release herein expresses a full and complete release and Executive intends the release herein to be final and complete. Executive executes this release with the full knowledge that
this release covers all possible claims against the Released Parties, to the fullest extent permitted by law. 
 3.4 Although this
Separation Agreement does not prevent Executive from participating in an investigation by the Equal Employment Opportunity Commission or similar state or local administrative agency, Executive expressly waives Executive’s right to recovery of
any type, including damages or reinstatement, in any administrative or court action, whether state or federal, and whether brought by Executive or on Executive’s behalf, related in any way to the matters released herein. 

4. California Civil Code Section 1542 Waiver. Executive expressly acknowledges and agrees that all rights under Section 1542 of
the California Civil Code are expressly waived. That section provides: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR
DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 

  
 2 

 5. Representation Concerning Filing of Legal Actions. Executive represents that, as of the date
of this Separation Agreement, Executive has not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against Company or any of the other Released Parties in any court or with any governmental agency. 

6. Mutual Nondisparagement. Executive agrees that Executive will not make any voluntary statements, written or oral, or cause or encourage
others to make any such statements that defame, disparage or in any way criticize the personal and/or business reputations, practices or conduct of Company or any of the other Released Parties. Similarly, Company and any Released Parties, through
their officers, directors, agents and Preferred Stockholders (if applicable), will not make any voluntary statements, written or oral, or cause or encourage others to make any such statements that defame, disparage or in any way criticize the
personal and/or business reputation, practices or conduct of Executive. 
 7. Confidentiality and Return of Company Property.
Executive understands and agrees that as a condition of receiving the Severance Package in paragraph 1, all company property, with the exception of the Company-issued property listed in paragraph 1.2 of this Separation Agreement, must be returned to
Company on or before the Separation Date. By signing this Separation Agreement, Executive represents and warrants that Executive will have returned to Company on or before the Separation Date, all Company property, data and information belonging to
Company and agrees that Executive will not use or disclose to others any confidential or proprietary information of Company or the Released Parties. In addition, Executive agrees to keep the terms of this Separation Agreement confidential between
Executive and Company, except that Executive may tell Executive’s immediate family and attorney or accountant, if any, as needed, but in no event should Executive discuss this Separation Agreement or its terms with any current or prospective
Executive of Company. 
 8. Continuing Obligations. Executive agrees to abide by the terms and conditions of the surviving
provisions of the Employment Agreement, which includes but is not limited to the arbitration and confidentiality provisions. 
 9. No
Other Severance. Executive acknowledges and agrees that the Severance Package provided pursuant to this Separation Agreement is in lieu of any other severance benefits to which Executive may be eligible under any other agreement and/or severance
plan or practice. 
 10. No Admissions. By entering into this Separation Agreement, the Released Parties make no admission that
they have engaged, or are now engaging, in any unlawful conduct. The parties understand and acknowledge that this Separation Agreement is not an admission of liability and shall not be used or construed as such in any legal or administrative
proceeding. 
 11. Older Workers’ Benefit Protection Act. This Separation Agreement is intended to satisfy the requirements of
the Older Workers’ Benefit Protection Act, 29 U.S.C. sec. 626(f) (“OWBPA”). Executive is advised to consult with an attorney before executing this Separation Agreement. 

11.1 Acknowledgments/Time to Consider. Executive acknowledges and agrees that (a) Executive has read and understands the terms of this
Separation Agreement; (b) Executive has been advised in writing to consult with an attorney before executing this Separation Agreement; (c) Executive has obtained and considered such legal counsel as Executive deems necessary;
(d) Executive has been given twenty-one (21) days to consider whether or not to enter into this Separation Agreement (although Executive may elect not to use the full 21-day period at Executive’s option); and (e) by signing this
Separation Agreement, Executive acknowledges that Executive does so freely, knowingly, and voluntarily. 
 11.2 Waiver of Consideration
Period. Executive waives the full 21-day period provided in paragraph 11.1 above. 

  
 3 

 11.3 Revocation/Effective Dates. With respect to all claims released by this Separation
Agreement, except the waiver of the ADEA Claims, this Separation Agreement shall become effective and enforceable on the day it is signed by Executive. Executive’s waiver of the ADEA Claims will become effective and enforceable on the
eighth day after Executive signs this Separation Agreement. In other words, Executive may revoke Executive’s acceptance of this Separation Agreement as to the ADEA Claims within seven (7) days after the date Executive signs it.
Executive’s revocation must be in writing and received by the Chairman of the Board by 5:00 p.m. Pacific Time on the seventh day in order to be effective. If Executive timely revokes, Executive’s ADEA Claims will survive the signing of
this Separation, and Executive hereby agrees to immediately return to Company $6,000.00 of the Severance Payment, if the Severance Payment has already been made. 
 11.4 Preserved Rights of Executive. This Separation Agreement does not waive or release any rights or claims that Executive may have under the ADEA that arise after the execution of this Separation
Agreement. In addition, this Agreement does not prohibit Executive from challenging the validity of this Separation Agreement’s waiver and release of claims under the ADEA. 

12. Severability. In the event any provision of this Separation Agreement shall be found unenforceable, the unenforceable provision shall be
deemed deleted and the validity and enforceability of the remaining provisions shall not be affected thereby. 
 13. Full Defense.
This Separation Agreement may be pled as a full and complete defense to, and may be used as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by Executive in breach hereof.

 14. Applicable Law. The validity, interpretation and performance of this Separation Agreement shall be construed and interpreted
according to the laws of the United States of America and the State of California. 
 15. Successors and Assigns. This Separation
Agreement is binding on Executive’s heirs, family members, executors, agents and assigns. 
 16. Counterparts. This Separation
Agreement may be signed in counterparts, and each shall be treated as though signed as one document. An executed signature page of this Separation Agreement delivered by facsimile or PDF transmission shall be as effective as an original executed
signature page. 
 17. Entire Agreement; Modification. This Separation Agreement, including the surviving provisions of the
Employment Agreement previously executed by Executive and herein incorporated by reference, is intended to be the entire agreement between the parties and supersedes and cancels any and all other and prior agreements, written or oral, between the
parties regarding this subject matter. This Separation Agreement may be amended only by a written instrument executed by all parties hereto. 
 [Remainder of Page Intentionally Left Blank] 

  
 4 

 THE PARTIES TO THIS SEPARATION AGREEMENT HAVE READ THE FOREGOING SEPARATION AGREEMENT AND FULLY UNDERSTAND EACH AND
EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS SEPARATION AGREEMENT ON THE DATES SHOWN BELOW. 
  

							
				
	Dated: January 13, 2012	 		 		 	 /s/ Gail A. Sloan

		 		 		 	Gail A. Sloan

  

							
		 		 	La Jolla Pharmaceutical Company
				
	Dated: January 16, 2012	 		 	By:	 	 /s/ Robert Fildes, Ph.D.

		 		 		 	Name: Robert Fildes, Ph.D.
		 		 		 	Its: Chairman of the Board

  

  
 Signature Page to
Confidential Separation Agreement and General Release of All ClaimsExhibit 10.4

 Exhibit 10.4 
 LA JOLLA PHARMACEUTICAL COMPANY 
 January 19, 2012 

George Tidmarsh, M.D., Ph.D. 
 Re: Offer of Employment 

Dear George: 
 La Jolla Pharmaceutical Company (the
“Company”) is pleased to offer you the full-time position of Chief Executive Officer and President. In conjunction with your employment, you will also serve as a member of the Board of Directors of the Company (the “Board”). Your
anticipated starting date will be January 19, 2012, effective upon the Closing (as defined in the Asset Purchase Agreement by and between the Company and Solana Therapeutics, Inc., dated January 19, 2012). This offer and your
employment relationship will be subject to the terms and conditions of this letter. 
 If you decide to join us, your initial annual base salary will be
$240,000, less applicable withholdings and deductions, paid in accordance with the Company’s normal payroll practices. Your annual base salary will be increased to $420,000 on the one-year anniversary of the date your employment commences (the
“Employment Start Date”). Thereafter, you will be considered for annual increases in base salary in accordance with Company policy and subject to review and approval by the Compensation Committee of the Board. 

In addition, on the date that is four weeks following the Conversion Price Adjustment Date (as defined in the Consent and Amendment Agreement by and among the
Company and the Holders (as defined therein) and dated as of January 19, 2012) you will be granted an option to purchase a number of shares of common stock of the Company equal to 7.5% of the Company’s fully diluted shares (on an
as-converted to common stock basis) outstanding on such date (the “First Option”) subject to the terms and conditions set forth in the La Jolla Pharmaceutical Company 2010 Equity Plan (the “Equity Plan”) and any applicable award
agreements and other restrictions and limitations generally applicable to common stock of the Company or equity awards held by Company executives or otherwise imposed by law. Subject to applicable terms and conditions, the First Option shall vest
with respect to 25% of the underlying shares on the one-year anniversary of the Employment Start Date and shall vest with respect to the remaining 75% of the underlying shares, monthly, in equal monthly installments, over the three years following
the one-year anniversary of the Employment Start Date. The First Option will be exercisable at a price equal to the fair market value of a share of common stock of the Company on the date of the grant of the First Option. 

On the two-year anniversary of the Employment Start Date, you will be granted an additional option to purchase a number of shares of common stock of the Company
equal to 7.5% of the Company’s fully diluted shares (on an as-converted to common stock basis) outstanding on such date less the number of shares underlying the First Option on the First Option grant date (as adjusted for stock splits, stock
dividends, combinations, recapitalizations, reclassifications or the like) (the “Second Option”), subject to the terms and conditions set forth in the Equity Plan and any applicable award agreement and other restrictions and limitations
generally applicable to common stock of the Company or equity awards held by Company executives or otherwise imposed by law. Subject to applicable terms and conditions, the Second Option shall vest with respect to 50% of the underlying

 
shares, immediately on the date of the grant and shall vest with respect to the remaining 50% of the underlying shares, monthly, in equal monthly installments, over the two years thereafter. The
Second Option will be exercisable at a price equal to the fair market value of a share of common stock of the Company on the date of the grant of the Second Option. 
 For clarity, during the time you are a member of the Board and also serving as the Company’s Chief Executive Officer and President, you will not be entitled to additional cash or equity compensation for
Board-related services. 
 During your employment, you will be eligible to participate in any and all employee benefit plans made available by the Company
from time to time to its executives generally, subject to plan terms and generally applicable Company policies. In addition to holidays observed by the Company, you will be eligible to earn and use vacation in accordance with the policies of the
Company, as in effect from time to time. Your initial vacation accrual will be at the rate of four weeks per year. The Company reserves the right to change or eliminate its benefits on a prospective basis at any time. 

You will be expected to devote your full business time and your best professional efforts, judgment, knowledge and skill exclusively to the performance of your
duties and responsibilities for the Company and its affiliates, and to abide by all Company policies and codes of conduct, as in effect from time to time, provided, however, that you may engage in business activities with Anavex Therapeutics and
Citizen’s Oncology Foundation, so long as you do not spend more than twenty (20) hours per month on activities relating to such entities and so long as your activities for such entities do not breach any terms of your employment or any
policies of the Company. As Chief Executive Officer and President, you will be expected to perform the duties of your position and such other duties as may be assigned to you from time to time. 

If you accept our offer, your employment with Company will be “at-will.” This means your employment is not for any specific period of time and can be
terminated by you at any time for any reason. Likewise, the Company may terminate the employment relationship at any time, with or without cause or advance notice. In addition, the Company reserves the right to modify your position, duties or
reporting relationship to meet business needs, and to use its managerial discretion in deciding on appropriate discipline when it deems circumstances so warrant. Any change to the at-will employment relationship must be by a specific, written
agreement signed by you and Company’s Chairman of the Board. 
 This offer is contingent upon the following: 

 

	 	•	 	 You signing and abiding by Company’s Proprietary Information, Nondisclosure, and Assignment Agreement (see enclosed); 

 

	 	•	 	 You signing the Company’s Mutual Agreement to Arbitrate (see enclosed); 

 

	 	•	 	 Your compliance with federal I-9 requirements (although you have three days to complete this process, please provide suitable documentation on your first day of
work verifying your identity and legal authorization to work in the United States). 

 This letter, including the enclosed Proprietary
Information, Nondisclosure, and Assignment Agreement and Mutual Agreement to Arbitrate, constitutes the entire agreement between you and Company relating to this subject matter, and supersedes all prior or contemporaneous agreements, understandings,
negotiations and representations, whether oral or written, express or implied, on this subject. This letter may not be modified or amended, and no breach is to be regarded as waived, unless agreed to in a specific, written agreement signed by you
and Company’s Board. This letter shall be governed and construed in accordance with the laws of the State of California, without regard to the conflict of laws principles thereof. 

 To indicate your acceptance of Company’s offer on the terms and conditions set forth in this letter, please sign
and date this letter in the space provided below and return it to our offices at 4370 La Jolla Village Drive, Suite 400, San Diego, CA 92122 or by email to gail.sloan@ljpc.com. If you do accept as provided, this letter will take effect as a binding
agreement between you and the Company on the date it is received, provided that you sign, date and return the Company’s Proprietary Information, Nondisclosure, and Assignment Agreement and Mutual Agreement to Arbitrate and satisfy the other
conditions set forth above in a timely manner. 
 We hope your employment with Company will prove mutually rewarding, and we look forward to having you
join us. If you have any questions, please feel free to call me at (858) 646-6644. 
 Sincerely, 

 

	
	
	/s/ Saiid Zarrabian
	Saiid Zarrabian
	Director

 * * * 
 Accepted and
agreed: 
  

							
				
	Dated January 19, 2012	 		 		 	/s/ George Tidmarsh
		 		 		 	George Tidmarsh

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]